Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in
epidermal growth factor receptor
(
EGFR
)-mutant non-small cell lung cancer (NSCLC)
J Thorac Dis
.
2022 Apr;14(4):816-819.
doi: 10.21037/jtd-22-98.
Authors
Giulio Metro
1
,
Angelo Bonaiti
1
,
Ilaria Birocchi
1
,
Francesca Marasciulo
1
,
Martina Ubaldi
1
,
Niccolò Metelli
1
,
Vincenzo Minotti
1
,
Alfredo Addeo
2
Affiliations
1
Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.
2
Department of Oncology, University Hospital of Geneva, Geneva, Switzerland.
PMID:
35572898
PMCID:
PMC9096286
DOI:
10.21037/jtd-22-98
No abstract available
Publication types
Editorial
Comment